Intensity Therapeutics Q3 Loss Widens as Trial Enrollment Resumes
Intensity Therapeutics reported a third-quarter 2026 net loss of $3.54 million on November 5, 2026, compared with $2.67 million in the same quarter of 2025, as new-patient enrollment activities resumed in its Phase 3 soft-tissue sarcoma study. The higher research spending behind the wider loss illustrates the cost of restarting development, with further Phase 3 expansion still conditional on new funding. Research and development expense rose 56% to $2.43 million from $1.55 million, while…